The Cooper Companies, Inc. (NASDAQ:COO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $84.7692.

Several equities research analysts recently commented on COO shares. The Goldman Sachs Group set a $64.00 price objective on shares of Cooper Companies and gave the stock a “sell” rating in a research report on Wednesday, October 1st. Mizuho decreased their price objective on shares of Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 16th. Stifel Nicolaus reduced their target price on shares of Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, August 28th. Barclays began coverage on shares of Cooper Companies in a report on Monday. They issued an “overweight” rating and a $85.00 target price on the stock. Finally, Robert W. Baird reduced their target price on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th.

Insider Buying and Selling

In other news, COO Daniel G. Mcbride bought 3,000 shares of Cooper Companies stock in a transaction on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the acquisition, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Brian G. Andrews bought 1,525 shares of Cooper Companies stock in a transaction on Tuesday, September 2nd. The stock was purchased at an average price of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the acquisition, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. This represents a 7.38% increase in their position. The disclosure for this purchase can be found here. Insiders bought 17,975 shares of company stock worth $1,216,346 in the last 90 days. 1.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of COO. Sustainable Growth Advisers LP acquired a new position in shares of Cooper Companies during the 2nd quarter valued at about $240,881,000. Ameriprise Financial Inc. increased its stake in shares of Cooper Companies by 98.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after acquiring an additional 1,683,561 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Cooper Companies by 7,723.3% during the 2nd quarter. Franklin Resources Inc. now owns 1,569,512 shares of the medical device company’s stock valued at $111,686,000 after acquiring an additional 1,549,450 shares during the last quarter. Findlay Park Partners LLP increased its stake in shares of Cooper Companies by 312.5% during the 2nd quarter. Findlay Park Partners LLP now owns 1,815,900 shares of the medical device company’s stock valued at $129,219,000 after acquiring an additional 1,375,657 shares during the last quarter. Finally, Soundwatch Capital LLC acquired a new position in shares of Cooper Companies during the 2nd quarter valued at about $607,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Price Performance

Cooper Companies stock opened at $71.97 on Friday. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $109.04. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The firm’s 50-day simple moving average is $69.51 and its 200 day simple moving average is $73.28. The firm has a market capitalization of $14.31 billion, a PE ratio of 35.45, a P/E/G ratio of 1.88 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the firm earned $0.96 EPS. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, equities research analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a share buyback plan on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.